PREDICTIVE VALUE OF VARIOUS PLATELET FUNCTION TESTS ON ST-SEGMENT RESOLUTION AND CLINICAL OUTCOME IN STEMI PATIENTS RANDOMIZED TO EITHER DUAL OR TRIPLE ANTIPLATELET THERAPY: THE ONTIME2 PLATELET FUNCTION SUBSTUDY  by Bouman, Heleen J. et al.
    
 i2 SUMMIT   
A207.E1948 
JACC March 9, 2010
Volume 55, issue 10A
PREDICTIVE VALUE OF VARIOUS PLATELET FUNCTION TESTS ON ST-SEGMENT RESOLUTION AND 
CLINICAL OUTCOME IN STEMI PATIENTS RANDOMIZED TO EITHER DUAL OR TRIPLE ANTIPLATELET 
THERAPY: THE ONTIME2 PLATELET FUNCTION SUBSTUDY
i2 Poster Contributions
Georgia World Congress Center, Hall B5
Monday, March 15, 2010, 3:30 p.m.-4:30 p.m.
Session Title: Pharmacotherapies and Complex Patients
Abstract Category: Pharmacotherapy - Interventional Aspects
Presentation Number: 2504-446
Authors: Heleen J. Bouman, Jochem W. van Werkum, Jaap J. Smit, Nicoline J. Breet, Sonja Postma, Ton Heestermans, Jurriën M. ten Berg, Robbert 
Slingerland, Christian M. Hackeng, Christian Hamm, Arnoud van ‘t Hof, Ongoing in Tirofiban in Myocardial Infarction Evaluation (ON-TIME) trial 
investigators, St. Antonius Hospital, Nieuwegein, The Netherlands, Isala Klinieken, Zwolle, The Netherlands
Background: Patients exhibiting high on-treatment platelet reactivity (HPR) despite antiplatelet therapy are at increased risk for the occurrence 
of thrombo-ischemic events. In this OnTIME2 platelet function substudy, we compared the antiplatelet effects of different pre-hospital initiated 
antiplatelet regimens and assessed the predictive value of different platelet function tests on ST-segment resolution, infarct-related vessel patency 
and clinical outcome including stent thrombosis.
Methods: ST-elevation myocardial infarction (STEMI) patients were pre-hospitally randomized to high dose tirofiban (HDT) or no HDT on top 
of clopidogrel and aspirin. The magnitude of on-treatment PR was evaluated in parallel using four different platelet function tests: two PFA-100 
cartridges (COL/EPI and COL/ADP), Fe-induced platelet aggregation (FIPA) and the Plateletworks® assay.
Results: Platelet function was evaluated in 458 patients. The magnitude of on-treatment HPR was significantly lower in patients randomized to HDT 
as compared to no HDT. All 4 platelet function tests showed a strong association between the level of on-treatment HPR and persistent ST-segment 
deviation at 1 hour. At 30 days of follow-up, the primary endpoint (a composite of all cause death, non-fatal myocardial infarction and stroke) 
occurred more frequently in patients exhibiting high on-treatment PR when measured with the PFA-100 COL/EPI cartridge. In multivariate analysis, 
high on-treatment platelet reactivity when measured with the PFA-100 COL/EPI cartridge remained an independent predictor of the primary endpoint 
at 30 days. 
Conclusions: Pre-hospital initiated triple antiplatelet therapy with HDT, clopidogrel and aspirin resulted in greater inhibition of platelet reactivity 
levels as compared to treatment with aspirin and clopidogrel alone. The PFA-100 COL/EPI cartridge is able to identify patients who are at higher risk 
for thrombo-ischemic events.
